Diversifying Businesses through Acquisitions, New Technologies and Next-Generation Products - Research Report on Medtronic, Abbott, Boston Scientific, St. Jude, and Cyberonics

NEW YORK, August 27, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Medtronic, Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Boston Scientific Corporation (NYSE: BSX), St. Jude Medical Inc. (NYSE: STJ), and Cyberonics Inc. (NASDAQ: CYBX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Medtronic, Inc. Research Report

On August 20, 2013, Medtronic, Inc. (Medtronic) reported its Q1 FY 2014 financial results (period ended July 26, 2013). Revenue increased 3% YoY on a constant currency basis to $4.1 billion. Reported net earnings totaled $953 million, or $0.93 per diluted share, up 10% YoY and 12% YoY, respectively. Commenting on the results, Omar Ishrak, Medtronic Chairman and CEO, stated, "Our Q1 results reflect that we are broadly outperforming our sector." Omar Ishrak added, "At the same time, we continue to strengthen and geographically diversify our business and remain confident in both our outlook for the remainder of the year and our long-term competitive position in the changing healthcare environment." The Company reaffirmed its full year FY 2014 outlook with revenue growth expected in the range of 3% to 4%, and diluted EPS in the range of $3.80 to $3.85. The Full Research Report on Medtronic, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-22/MDT]

--

Abbott Laboratories Research Report

On August 21, 2013, Abbott Laboratories (Abbott) announced the completion of its acquisition of IDEV Technologies, a privately held company focused on developing next-generation medical devices. "Peripheral artery disease is a significant and growing health concern around the world, raising the need for new and effective treatment options," said Chuck Foltz, Senior Vice President, Vascular at Abbott. "Abbott's acquisition of IDEV Technologies strengthens our global product portfolio while providing an additional opportunity to make a positive impact in the lives of patients with peripheral artery disease." According to Abbott, it has also acquired all outstanding equity of IDEV Technologies for $310 million net of cash and debt. The Full Research Report on Abbott Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-22/ABT]

--

Boston Scientific Corporation Research Report

On August 21, 2013, Boston Scientific Corp. (Boston Scientific) announced that its IntellaTip MiFi™ XP catheter and 510(k) clearance of its Zurpaz™ 8.5F steerable sheath has received US Food and Drug Administration (FDA) approval. Pete Sommerness, General Manager, Electrophysiology, Boston Scientific, commented, "We believe that the IntellaTip MiFi XP approval, combined with the introduction of our Zurpaz steerable sheath, demonstrates how we are delivering on our promise to provide electrophysiologists with meaningful innovation and complete solutions." According to the Company, catheter ablation has become a first-line treatment approach for patients with certain kinds of irregular heartbeats. The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-22/BSX]

--

St. Jude Medical Inc. Research Report

On August 19, 2013, St. Jude Medical Inc. (St. Jude Medical) announced the acquisition of Endosense SA, a pioneer in contact-force measurement in catheter ablation. Commenting on the acquisition, Frank J. Callaghan, President of the Cardiovascular and Ablation Technologies Division of St. Jude Medical, stated, "This transaction significantly accelerates our timeline to providing an irrigated ablation catheter that incorporates force sensing in both international and U.S. markets, and has potential future applications across other St. Jude Medical technology platforms as well.". According to St. Jude Medical, the acquisition adds to the company's leading electrophysiology portfolio and provides a robust platform for future product development. The Full Research Report on St. Jude Medical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-22/STJ]

--

Cyberonics Inc. Research Report

On August 22, 2013, Cyberonics Inc. (Cyberonics) reported its Q1 FY 2014 financial results (period ended July 26, 2013). The Company reported net product sales of $67.4 million, a 12.4% YoY increase. Net sales (including $1.5 million of license revenue) grew 14.2% YoY to $68.9 million. Adjusted non-GAAP income from operations was up 21.9% YoY to $21 million. Adjusted non-GAAP income per diluted share increased 27.9% YoY to $0.48. Commenting on the results, Dan Moore, Cyberonics' President and CEO, stated, "Net sales in the first quarter of fiscal 2014 met our expectations and provides a good start to the fiscal year." Dan Moore added, "Adjusted EBITDA for the first quarter was $25.6 million, and with our available cash and short-term investments of $131 million, the company is well-positioned to continue to deliver stockholder value with investments in next-generation products and stock repurchases." The Company has reaffirmed its fiscal 2014 guidance with net sales to be in the range of $279 million to $283 million, and adjusted non-GAAP income per diluted share (EPS) to be in the range of $1.93 to $2.01. The Full Research Report on Cyberonics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-22/CYBX]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports